Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 12/2003

01-12-2003 | Case Report

A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody

Authors: Dany Gholam, Jean-Marie Vantelon, Ahmad Al-Jijakli, Jean-Henri Bourhis

Published in: Annals of Hematology | Issue 12/2003

Login to get access

Abstract

Multicentric Castleman's disease (MCD) is a rare systemic lymphoproliferative disorder with too few patient series reported in the literature to have a clear idea about the etiology, outcome and the best treatment available. Systemic reactive amyloidosis is a very rare complication of MCD and its presence worsens the prognosis. We report a case of a 28-year-old patient with plasma-cell type, human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative MCD who responded to treatment with chemotherapy and the anti-CD20 monoclonal antibody, rituximab. Anti-CD20 therapy could be an interesting adjunctive treatment in MCD.
Literature
1.
Keller A, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683PubMed
2.
Flendrig J, Schillings PHM (1969) Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl 12:119
3.
Peterson B, Frizzera G (1993) Multicentric Castleman's disease. Semin Oncol 20:636–647PubMed
4.
Chronowski G, Ha C, Wilder R et al (2001) Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 92:670–676CrossRefPubMed
5.
Katano H, Sata T (1999) An attractive relation of human herpesvirus-8 with multicentric Castleman's disease. Intern Med 38:221–222PubMed
6.
Hayashi M, Aoshiba K, Shimada M et al (1999) Kaposi's sarcoma-associated herpesvirus infection in the lung in multicentric Castleman's disease. Intern Med 38:279–282PubMed
7.
Bowne W, Lewis J, Filippa D, et al (1999) The management of unicentric and multicentric Castleman's disease. Cancer 85:706–717PubMed
8.
Andres E, Maloisel F (2000) Interferon-α as first-line therapy for treatment of multicentric Castleman's disease. Ann Oncol 11:1613–1614CrossRefPubMed
9.
Rieu P, Droz D, Gessain A et al (1999) Retinoic acid for treatment of multicentric Castleman's disease. Lancet 354:1262–1263CrossRefPubMed
10.
Nishimoto N, Sasai M, Shima Y, Nakagawa M et al (2000) Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:56–61PubMed
11.
Corbellino M, Bestetti G, Scalamogna C et al (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 12:3473–3475CrossRef
12.
Suda T, Katano H, Delsol G, Kakiuchi C, Nakamura T et al (2001) HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int 51:671–679CrossRefPubMed
13.
Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M et al (2002) Update on Kaposi's sarcoma and other HHV-8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2:344–352CrossRefPubMed
14.
West KP, Morgan DR, Lauder I (1989) Angiofollicular lymph node hyperplasia with amyloidosis. Postgrad Med J 65:108–111PubMed
15.
Ordi J, Grau JM, Junque A, Nomdeleu B, Palacin A, Cardesa A (1993) Secondary (AA) amyloidosis associated with Castleman's disease. Am J Clin Pathol 100:394–397PubMed
16.
Miura A, Saro I, Suzuki C (1995) Fatal diarrhea in a patient with Castleman's disease associated with intestinal amyloidosis. Intern Med 34:1106–1109PubMed
17.
Tanaka K, Horita M, Shibayama H, Seike M, Itoh Y et al (1995) Secondary amyloidosis associated with Castleman's disease. Intern Med 34:122–126PubMed
18.
Funabiki K, Kaneko S, Terajima M, Tomita H, Kawano Y, Tomino Y (1998) A case of multicentric Castleman's disease associated with renal amyloidosis and pure red cell aplasia. Am J Nephrol 18:247–250PubMed
19.
Altiparmak MR, Pamuk GE, Pamuk ON, Dogusoy G (2002) Secondary amyloidosis in Castleman's disease: review of the literature and report of a case. Ann Hematol 81:336–339CrossRefPubMed
20.
Derici U, Arinsoy T, Ataoglu O, Bali M, Sindel S et al (2002) Localized Castleman's disease and nephrotic syndrome not responsive to resection plus colchicine therapy. Ann Hematol 81:399–401CrossRefPubMed
21.
Sezer O, Eucker J, Schmid P, Possinger K (2000) New therapeutic approaches in primary systemic AL amyloidosis. Ann Hematol 79:1-6CrossRefPubMed
22.
Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA (1999) Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 17:262–267PubMed
23.
Van Eygen K, Zachee P, Maertens J, Vandenberghe P, Demuynck H, Verhoef G, Boogaerts A (1996) Treatment of primary amyloidosis with VAD combination chemotherapy results in improved survival. Blood 88(1):591a
24.
Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone and melaphalan, prednisone and colchicine. N Engl J Med 336:1202–1207CrossRefPubMed
Metadata
Title
A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody
Authors
Dany Gholam
Jean-Marie Vantelon
Ahmad Al-Jijakli
Jean-Henri Bourhis
Publication date
01-12-2003
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 12/2003
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-003-0718-x

Other articles of this Issue 12/2003

Annals of Hematology 12/2003 Go to the issue

Original Article

Dynamics of circulating t(14;18)-positive cells during first-line and subsequent lines of treatment in follicular lymphoma

Original Article

Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias

Original Article

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

Original Article

A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses

Case Report

Autoimmune hemolytic anemia as a first manifestation of primary effusion lymphoma

Case Report

Hereditary spherocytosis associated with mutations in HFE gene
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits